Reply to: Safety of dopamine agonists for treating restless legs syndrome
Mov Disord
.
2019 Jan;34(1):150-151.
doi: 10.1002/mds.27571.
Authors
Aaro V Salminen
1
,
Richard P Allen
2
3
,
Birgit Högl
4
,
Yuichi Inoue
5
6
,
Wolfgang Oertel
7
,
John W Winkelman
8
9
,
Claudia Trenkwalder
10
11
,
Cristina Sampaio
12
,
Juliane Winkelmann
1
13
14
Affiliations
1
Institute of Neurogenomics, Helmholtz Zentrum München, Munich, Germany.
2
Sleep Disorders Center, Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States.
3
Department of Neurology, Johns Hopkins University, Baltimore, Maryland, United States.
4
Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
5
Japan Somnology Center, Neuropsychiatric Research Institute, Tokyo, Japan.
6
Department of Somnology, Tokyo Medical University, Tokyo, Japan.
7
Department of Neurology, Philipps-Universität Marburg, Marburg, Germany.
8
Harvard Medical School, Boston, Massachusetts, United States.
9
Departments of Psychiatry and Neurology, Massachusetts General Hospital, Boston, MA, United States.
10
Department Neurosurgery, University Medical Center, Goettingen, Germany.
11
Paracelsus-Elena Hospital, Kassel, Germany.
12
CHDI Foundation, Princeton, New Jersey, USA.
13
Chair Neurogenetics and Institute of Human Genetics, Technical University Munich, Germany.
14
Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
PMID:
30653723
DOI:
10.1002/mds.27571
No abstract available
Publication types
Letter
Comment
MeSH terms
Dopamine Agonists
Humans
Restless Legs Syndrome*
Substances
Dopamine Agonists